- The FDA has approved Nextstellis (3 mg, DRSP, and 14.2 mg, E4 tablets) for the prevention of pregnancy and is expected to be commercially available in Jun’2021
- The P-III study demonstrated the efficacy of Nextstellis across all subgroups through age, BMI and prior hormonal contraception use. The therapy is also associated with favorable bleeding control, including in cycle 1.
- Nextstellis is the 1st oral contraceptive pill containing E4 and is safe, effective, and well-tolerated in clinical trials with a desirable bleeding profile and minimal impact on triglycerides, cholesterol, glucose, as well as weight and endocrine markers
Click here to read full press release/ article | Ref: PRNewswire| Image: Mayne Pharma